

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Aranda Richard</u>			2. Date of Event Requiring Statement (Month/Day/Year) <u>06/21/2021</u>		3. Issuer Name and Ticker or Trading Symbol <u>Gossamer Bio, Inc. [GOSS]</u>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Medical Officer</u>			5. If Amendment, Date of Original Filed (Month/Day/Year)	
<u>3013 SCIENCE PARK ROAD</u>							
(Street) <u>SAN DIEGO CA 92121</u>						6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>204,809⁽¹⁾</u>	<u>D</u>	
<u>Common Stock</u>	<u>2,539</u>	<u>I</u>	<u>By family trust</u>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Stock Option (Right to Buy)</u>	<u>(2)</u>	<u>12/10/2028</u>	<u>Common Stock</u>	<u>38,666</u>	<u>10.71</u>	<u>D</u>
<u>Stock Option (Right to Buy)</u>	<u>(3)</u>	<u>03/25/2029</u>	<u>Common Stock</u>	<u>45,000</u>	<u>22.1</u>	<u>D</u>
<u>Stock Option (Right to Buy)</u>	<u>(4)</u>	<u>12/23/2029</u>	<u>Common Stock</u>	<u>13,750</u>	<u>16.4</u>	<u>D</u>
<u>Stock Option (Right to Buy)</u>	<u>(5)</u>	<u>02/14/2030</u>	<u>Common Stock</u>	<u>34,175</u>	<u>14.55</u>	<u>D</u>
<u>Stock Option (Right to Buy)</u>	<u>(6)</u>	<u>02/25/2031</u>	<u>Common Stock</u>	<u>60,000</u>	<u>9.79</u>	<u>D</u>

Explanation of Responses:

- Includes 13,838 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Also includes 65,247 restricted stock units, which shares will vest in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
- 24,180 shares subject to the option have vested and are fully exercisable and 1/48th of the total number of shares subject to the option vest on July 10, 2021 and the last day of each one-month period thereafter through December 10, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
- 24,375 shares subject to the option have vested and are fully exercisable and 1/48th of the total number of shares subject to the option vest on June 25, 2021 and the last day of each one-month period thereafter through March 25, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
- 4,869 shares subject to the option have vested and are fully exercisable and 1/48th of the total number of shares subject to the option vest on June 23, 2021 and the last day of each one-month period thereafter through December 23, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
- 11,391 shares subject to the option have vested and are fully exercisable and 1/48th of the total number of shares subject to the option vest on July 14, 2021 and the last day of each one-month period thereafter through February 14, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
- 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Remarks:

/s/ Jeff Boerneke, Attorney-in-Fact

06/22/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Christian Waage and Jeff Boerneke, signi

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commi:
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Gossamer Bio, Inc.,
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, ma

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing wha

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of June 2021.

Signature: /s/ Richard Aranda

Print Name: Richard Aranda